lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
Published 3 years ago • 299 plays • Length 4:08Download video MP4
Download video MP3
Similar videos
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
11:23
therap study: lu-psma vs. cabazitaxel #asco20 #anzup
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
9:29
anzup therap study @ asco gu 2021
-
4:00
therap trial and effectiveness of lu-psma-617
-
0:51
therap trial of 177lu-psma-617 review | david vanderweele, md | asco22 prostate cancer updates
-
4:48
vision: lu-177-psma-617 in mcrpc
-
2:46
upfrontpsma trial: 177lu-psma-617 and docetaxel in mhnpc
-
3:41
177lu-psma-617 vs. cabazitaxel for mcrpc
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
10:47
therap trial
-
14:37
lupsma: the newest treatment class for advanced prostate cancer
-
7:14
vision study
-
6:24
phase iii study of lutetium-177-psma-617 in patients with metastatic castration-resistant prosta...
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
0:16
lutetium-177 psma therapy
-
15:35
lu-psma radioligand therapy